Am I part of the cure, or am I part of the disease

Jens Lundgren | Mar 2020 | COVID-19 |

Jens Lundgren
Professor of infectious diseases,
practicing infectious disease specialist,
Department of infectious diseases,
Rigshospitalet,
University of Copenhagen,
Denmark

This COVID-19 perspective was produced by Professor Jens D. Lundgren - one of the world’s leading infectious disease specialists. Jens. D. Lundgren is currently leading a clinical trial of investigational vaccine designed to protect against COVID-19. Jens D. Lundgren is also the founder and member of the steering committee of the HIV in Europe Initiative and in 2015 he was awarded the EACS Award for Excellence in HIV Medicine.     Monday 23th. March 2020  Am I Part of the Cure or Am I Part of the Disease? A colleague of mine Christian Rose from the Center for Primary Care and Outcomes Research, Stanford University, has written about, how health care workers are experiencing social stigma during the current outbreak of COVID-19.( https://www.nejm.org/doi/full/10.1056/NEJMp2004768?query=featured_home )1 I believe that many health care workers in our health care system are having the same considerations during this period: We need to share and address these thoughts and worries, that we all have. As Christian Rose puts it: “Times like this can leave physicians stranded between our commitment to the community and responsibility to our families — a no man’s land, where a colleague’s spare bed may be the closest approximation of home that we can find.” The current testing situation Last Friday it was announced that Denmark was close to running out of coronavirus testing kits. I am convinced that everyone can agree upon, that it is time to prioritize the testing. We need to assure a certain test activity, when the outbreak peaks. The Chinese had the same problem. They developed a clinical case definition and if patients fulfilled the criteria of the clinical case definition, no test was done. Furthermore, the plan B is, that test analysis should be done via non-commercial in-house technologies. We are currently working hard to solve this. Access to hydroxychloroquin During...